drugset / Trial / NCT00300274
Efficacy and Safety of Everolimus in Recipients of Heart Transplants to Prevent Acute and Chronic Rejection
RandomizedParallel-groupOpen-labelTreatment
Summary
This trial was to examine the impact of everolimus and reduced dose of cyclosporine on efficacy and safety compared to mycophenolate mofetil and a standard dose of cyclosporine in heart transplant recipients.
Timeline
- Start
- 2006-01
- Primary completion
- 2011-07
- Completion
- 2011-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclosporine | Peptide | — | — |
| Subject | Everolimus | Small molecule | 0.75 mg | — |
| Subject | Everolimus | Small molecule | 1.5 mg | — |
| Comparator | Mycophenolate Mofetil | Small molecule | 1500 mg | — |